NuVasive Investor Relations

NuVasive is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes.

Press Release

NuVasive Unveils Latest Innovation At NASS 2017
NuVasive showcases new innovation including XLIF® Crestline™, Lateral ALIF, Modulus™ XLIF, TLX™ system, LessRay® and porous PEEK technology, along with new Advanced Materials Science™ portfolio; Company celebrates 15 years of leading lateral spine surgery with XLIF procedure

SAN DIEGO, Oct. 25, 2017 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced it will highlight the Company's latest disruptive spine technology innovation at the North American Spine Society (NASS) Annual Meeting held October 25-28, 2017 in Orlando, Fla. At the event, NuVasive will also celebrate 15 years of leading lateral spine surgery with the Company's flagship XLIF procedure, highlighting its commitment to lead, expand and advance spine technology.

"Now more than ever, NuVasive is expanding our portfolio with an unprecedented number of product launches covering spine's leading procedures, materials, expandables and systems," said Matt Link, executive vice president, strategy, technology and corporate development of NuVasive. "The NuVasive leadership team remains committed to furthering its investment in R&D and bringing both first-of-its-kind platforms and disruptive technology to market. Our comprehensive portfolio will continue to reflect the needs of our surgeon partners and provide better and more predictable outcomes for patients."

Lateral Procedural Solutions
NuVasive is expanding its lateral procedural solutions with Lateral ALIF, XLIF Crestline and Lateral MAS® Fixation, enabling surgeons to treat pathologies from T6-S1 for true, lateral single-position surgery. The Lateral ALIF procedure is designed to provide direct access to L5-S1 with the patient in a lateral decubitus position, with the characteristics of a traditional supine ALIF. Built on the XLIF platform, XLIF Crestline is a supplemental solution, designed to gain lateral access to challenging L4-L5 levels, such as high crest, anterior psoas or an anterior plexus. Lateral Maximum Access Surgery (MAS) Fixation is an adapted technique utilizing Reline®, the Company's innovative fixation system designed to preserve and restore spinal alignment.

Advanced Materials Science (AMS) Portfolio
The Company's AMS portfolio is designed to deliver enhanced osseointegration and biomechanics through innovative implant design. With leading advanced materials in surface, structure and imaging characteristics, the portfolio includes the Company's recently launched Modulus XLIF, its 3D-printed porous titanium implant, porous PEEK (polyetheretherketone) technology following last month's acquisition of Vertera Spine, including the COHERE® cervical interbody fusion device. The Company's future plans include integrating the porous PEEK technology across all its procedural offerings. NuVasive is the only medical device company to offer porous interbody technology across both porous PEEK and titanium materials, thereby addressing the spectrum of surgeons' needs and preferences for advanced interbody implants.

Radiation Reduction Platform
The Company's LessRay system, comprised of a propriety software algorithm and hardware components, is designed to help address overexposure to radiation in hospital operating rooms (O.R.), particularly in the case of minimally invasive spine surgery. LessRay's proprietary image enhancement technology improves low-dose, low-radiation fluoroscopy (or x-ray) images to have similar diagnostic capabilities as conventional full-dose fluoroscopy images, thereby reducing radiation emission and exposure in the O.R. while retaining the high resolution of a full radiation dose shot. Additionally, LessRay has other features to help reduce the number of fluoroscopic shots needed, thus decreasing the overall radiation even further.

3D Printed Cages – Expandable Cages
Modulus XLIF is a 3D-printed, porous titanium implant developed to create an organic architecture that mimics the porosity and stiffness of bone for reduced stress shielding. The device's optimized architecture also leads to improved imaging characteristics compared to traditional titanium interbody devices. The TLX interbody system is a market-leading solution that is inserted through a conventional transforaminal lumbar interbody fusion (TLIF) approach. NuVasive developed a minimally invasive approach for the TLIF procedure, the MAS TLIF. Designed to be used with this MIS approach, TLX implants can be placed seamlessly into the disc space due to their low profile, bulleted design. The TLX interbody system now includes an expandable 20 degree cage.

NuVasive 2017 NASS Annual Meeting Participation Details
NuVasive will showcase its innovation in NuVasive Booth #713 and #959 at the NASS Annual Meeting held October 25-28, 2017 in Orlando, Fla.

The Company also will host a surgical innovation lab demonstration presented by Robert Isaacs, MD, Mark Medley, MD, William D. Smith, MD, and J. Alex Thomas, MD, titled "Single Position Lateral Solutions to Treat L4-S1, Featuring Advanced 3D Printed Implants and LessRay Radiation Emission Reduction Technology" on October 26, 2017 from 8:00 a.m. to 10:00 a.m. in the Green Lab at the Orange County Convention Center.

Visit here for more details and schedule of events.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally invasive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

 

 

View original content with multimedia:http://www.prnewswire.com/news-releases/nuvasive-unveils-latest-innovation-at-nass-2017-300542816.html

SOURCE NuVasive, Inc.

Investor: Suzanne Hatcher, NuVasive, Inc., 858-458-2240, investorrelations@nuvasive.com; or Media: Stefanie Mazer, NuVasive, Inc., 858-320-5243, media@nuvasive.com